Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Maze- Sanofi deal in Pompe shows how early clinical data can drive pharma deals

Pharma extends rare disease franchise, paying well-funded biotech $150M in cash and equity investment to embrace substrate reduction approach

May 1, 2023 10:02 AM UTC

A deal with Maze will give Sanofi rights to an oral therapy for Pompe disease, strengthening the pharma’s armamentarium against the disorder with a substrate reduction approach that may be paired with approved enzyme replacement therapies.

Sanofi (Euronext:SAN; NASDAQ:SNY) is paying $150 million in cash, including a future equity investment in privately held Maze Therapeutics Inc., for rights to the biotech’s GYS1 inhibitor MZE001. The molecule has generated Phase I data showing reductions in glycogen synthesis and total glycogen production, as well as glycogen biomarker data in peripheral blood as a surrogate measurement for muscle glycogen...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article